Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Botanix Pharmaceuticals Limited ( (AU:BOT) ) is now available.
Botanix Pharmaceuticals Limited has announced a buy-back of ordinary fully paid shares under an employee share scheme. This move is part of the company’s strategy to manage its capital structure and incentivize its employees, potentially enhancing shareholder value and aligning employee interests with company goals.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development and commercialization of dermatology and antimicrobial products. The company aims to address unmet needs in skin diseases and infections, leveraging its proprietary drug delivery technology.
Average Trading Volume: 6,485,588
Technical Sentiment Signal: Sell
Current Market Cap: A$226.6M
See more insights into BOT stock on TipRanks’ Stock Analysis page.